Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study

Wei, Jinli; Zhang, Jiaxin; Fu, Deyuan

doi:10.1186/s12957-018-1539-7

Cited by 9 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we found that there was a significant difference in OS but no difference in DSS between different HER2 status in univariable Cox regression analysis. Wei JL et al30 found that chemotherapy is independently associated with OS, but chemotherapy has no effect on DSS in MBC patients, which is the same as the current results. Besides, few studies analyzed OS and DSS of MBC at the same time.…”

Section: Discussionsupporting

confidence: 90%

<p>Effects of HER2 status on the prognosis of male breast cancer: a population-based study</p>

Chen

Weng

et al. 2019

OTT

View full text Add to dashboard Cite

ObjectiveThis study was designed to analyze the effects of human epidermal growth factor receptor-2 (HER2) status on the prognosis of male breast cancer (MBC).MethodsThe SEER database was used to identify MBC patients diagnosed between 2010 and 2015. Patients were divided into HER2-negative and HER2-positive groups and chi-square test was used to compare the demographics. Propensity score matching (PSM) was used to remove confounding factors. The log-rank test was used to compare the overall survival (OS) and disease-specific survival (DSS) between the two groups. Univariate and multivariate Cox regression analyses were used to evaluate the effects of different variables on the prognosis of MBC patients. Subgroup analysis was conducted by using R software to explore the benefit of OS and DSS in the subgroup of MBC patients.ResultsIn the matched cohort, the log-rank test showed that there was a longer OS (P=0.044) in the HER2-negative group, and the 4-year OS rate in HER2-negative patients was significantly improved (P=0.008), but there was no difference in the DSS (P=0.408) and the 4-year DSS rates (P=0.198) between the two groups. Univariate and multivariate Cox regression also showed that the HER2 status did not independently associate with DSS (P=0.444). Subgroup analysis showed that HER2-negative patients experienced a longer OS in the subgroup of tumors 2–4 cm in size, no distant metastasis and who had received radiotherapy, but none of subgroup was found a significant difference in DSS between different HER2 status.ConclusionThis study identified that HER2 status had a clear influence on OS in patients with MBC, and there was a longer OS and a higher 4-year OS rate in the HER2-negative group. In addition, we observed that HER2 status had no significant effect on DSS in patients with MBC.

show abstract

Section: Discussionsupporting

confidence: 90%

<p>Effects of HER2 status on the prognosis of male breast cancer: a population-based study</p>

Chen

Weng

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…However, these studies did not further Regardless of matching patients by baseline characteristics, adjuvant chemotherapy was significantly associated with OS but not with BCSS, consistent with the results of the previous studies. 21,23 Furthermore, our study showed that adjuvant chemotherapy was not associated with BCSS in patients stratified by grade, stage, receptors status, tumour size and LN status. This means that adjuvant chemotherapy could reduce the risk of dying from all causes but not the risk of dying from breast cancer.…”

Section: Table 1 (Continued)mentioning

confidence: 64%

“…10 Several large clinical trials have shown that some women with breast tumour >1 cm may avoid adjuvant chemotherapy without reducing the overall survival rate. 11 For example, the TAILORx trial 12,13 was a prospective and randomized trial for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, stage T1-2, lymph node-negative and recurrence score (RS) of 11-25 breast cancers (HR+, HER2-, T1-2, N0, M0, RS [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25], in which the patients received adjuvant endocrine therapy alone or adjuvant chemotherapy followed by endocrine therapy. The two groups had similar treatment efficacy and no significant differences in disease-free survival (DFS) or overall survival (OS).…”

Section: Introductionmentioning

confidence: 99%

The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

Gao

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no signiﬁcant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

show abstract

“…Similarly, some studies found that radiotherapy after mastectomy improved local tumor control but did not affect the survival rate. 25,26 Wei et al 27 established that chemotherapy was a significant factor only in the OS but not in the BCSS in patients with MBC. The possible reasons are as follows: (1) As most MBCs are hormone receptor dependent, patients benefit more from endocrine therapy than chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

A Novel Nomogram for Predicting Breast Cancer–specific Survival in Male Patients

Zhou¹,

Zhang²,

Zhao³

et al. 2022

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: To compare breast cancer-specific survival (BCSS) of nonmetastatic invasive breast cancer between male (MBC) and female (FBC) patients, define clinicopathologic variables related to BCSS in nonmetastatic invasive MBC patients, and establish a nomogram for individual risk prediction.Materials and Methods: On the basis of Surveillance, Epidemiology, and End Results database, 2094 MBC and 48,104 FBC cases underwent propensity score matching (PSM). We compared the prognosis of patients before and after PSM and developed a nomogram for BCSS of nonmetastatic invasive MBC patients. Internal validation was performed using the consistency index, calibration curves, and receiver operating characteristic curves. Simultaneously, data from 49 nonmetastatic invasive MBC patients diagnosed between January 2012 and May 2016 were collected for external validation.Results: Before PSM, overall survival and BCSS were significantly shorter in MBC than those in FBC patients. After PSM, MBC patients continued to have a shorter overall survival, but not BCSS, than FBC patients. Marital status, age, histologic grade, estrogen/progesterone receptor status, Tumor Lymph Node stage, and surgery were included in the prediction model. Conclusions:The nomogram developed in this study seems to be more accurate than conventional Tumor-nodal-metastasis staging staging to predict BCSS and may serve as an effective tool for assessing the prognosis of nonmetastatic invasive MBC.

show abstract

Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study

Cited by 9 publications

References 30 publications

<p>Effects of HER2 status on the prognosis of male breast cancer: a population-based study</p>

<p>Effects of HER2 status on the prognosis of male breast cancer: a population-based study</p>

The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

A Novel Nomogram for Predicting Breast Cancer–specific Survival in Male Patients

Contact Info

Product

Resources

About